The global cancer biopsy market was valued at US$ 24.7 Bn in 2022 and is projected to grow at a CAGR of 11.4% from 2023 to 2031, reaching more than US$ 66.0 Bn by 2031. The market is witnessing strong growth as cancer incidence continues to rise worldwide and healthcare providers increasingly adopt advanced diagnostic technologies.

Growing Cancer Burden Fuels Market Expansion

The increasing prevalence of cancer and growth in the geriatric population are among the major factors driving demand for cancer biopsy procedures. Biopsy remains an essential diagnostic tool for determining whether abnormal tissue contains cancer cells and identifying the specific type of cancer. Growing awareness regarding early cancer detection is also encouraging patients and healthcare providers to pursue timely diagnostic testing.

Advances in medical technology are further improving the accuracy, efficiency, and convenience of biopsy procedures. Traditional needle, surgical, and endoscopic biopsies are increasingly complemented by advanced approaches designed to provide more precise diagnostic information.

Liquid Biopsy Emerges as a Major Growth Opportunity

Liquid biopsy has emerged as one of the most transformative technologies in cancer diagnostics. Unlike conventional tissue biopsy, liquid biopsy can analyze tumor-derived genetic material from blood and other bodily fluids, offering a minimally invasive approach for cancer detection and monitoring.

The technology is gaining traction for cancer screening, prognosis, recurrence monitoring, and treatment selection. Increasing demand for personalized medicine is expected to further accelerate adoption, as liquid biopsies can help identify genetic alterations that may guide targeted therapies.

Technological advancements are also supporting the growth of the kits and reagents segment. The availability of sophisticated diagnostic kits and reagents is helping laboratories and healthcare providers improve testing capabilities as cancer patient volumes increase.

Breast Cancer Application Remains Prominent

Breast cancer represents a significant application area within the cancer biopsy market. Rising incidence of breast cancer worldwide is increasing demand for biopsy procedures used to confirm suspected tumors and support treatment planning. Core-needle biopsy is increasingly preferred in appropriate cases because it can provide diagnostic tissue samples while being less invasive than surgical biopsy.

The growing emphasis on early detection and improved breast cancer screening infrastructure is expected to sustain demand for biopsy technologies throughout the forecast period.

Get Sample PDF:

North America Leads, Asia Pacific Shows Strong Potential

North America accounted for a significant share of the global cancer biopsy market in 2022, supported by advanced healthcare infrastructure, high cancer prevalence, technological innovation, and increasing product launches and approvals. The United States remains an important market for liquid biopsy research, clinical adoption, and personalized oncology.

Meanwhile, Asia Pacific is expected to experience robust growth through 2031. Rising cancer incidence, expanding healthcare infrastructure, growing awareness of early diagnosis, and increasing adoption of minimally invasive diagnostic procedures are creating new opportunities across the region.

Competitive Landscape and Future Outlook

Leading companies operating in the cancer biopsy market include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Illumina, Inc., Siemens Healthineers, GE Healthcare, Bio-Rad Laboratories, Inc., QIAGEN, and Olympus Corporation.

Companies are focusing on product launches, strategic collaborations, partnerships, and technological development to strengthen their market positions. Continued innovation in liquid biopsy, molecular diagnostics, and minimally invasive biopsy techniques is expected to create significant growth opportunities.

With the global cancer burden increasing and precision oncology gaining momentum, the cancer biopsy market is poised for substantial expansion, reaching more than US$ 66.0 Bn by 2031.